Overview

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Antengene Biologics Limited